Last reviewed · How we verify
AJ201
At a glance
| Generic name | AJ201 |
|---|---|
| Also known as | JM17 |
| Sponsor | AnnJi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AJ201 CI brief — competitive landscape report
- AJ201 updates RSS · CI watch RSS
- AnnJi Pharmaceutical Co., Ltd. portfolio CI